Brief: Argenx Announces FDA Approval Of Vyvgart Hytrulo Prefilled Syringe For Self-Injection In Generalized Myasthenia Gravis And Chronic Inflammatory Demyelinating Polyneuropathy
10/04/2025 22:52
April 10 (Reuters) - argenx SE ARGX.BR: ARGENX ANNOUNCES FDA APPROVAL OF VYVGART HYTRULO PREFILLED SYRINGE FOR SELF-INJECTION IN GENERALIZED MYASTHENIA GRAVIS AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY Source text: ID:nGNX9nvb89 Further company coverage: ARGX.BR ((Reuters.Briefs@thomsonreuters.com;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles